Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:HSP
- CUSIP: 44106010
- Web: N/A
- 50 Day Moving Avg: $90.00
- 200 Day Moving Avg: $88.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 24.58
- P/E Growth: 0
Frequently Asked Questions for Hospira (NYSE:HSP)
What is Hospira's stock symbol?
Hospira trades on the New York Stock Exchange (NYSE) under the ticker symbol "HSP."
How were Hospira's earnings last quarter?
Hospira, Inc. (NYSE:HSP) announced its earnings results on Wednesday, July, 29th. The company reported $0.85 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.78 by $0.07. The company earned $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Hospira's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.72 earnings per share. View Hospira's Earnings History.
Who are some of Hospira's key competitors?
Some companies that are related to Hospira include Zoetis (ZTS), Mylan (MYL), Catalent (CTLT), Neurocrine Biosciences (NBIX), Akorn (AKRX), Mallinckrodt PLC (MNK), The Medicines Company (MDCO), Ironwood Pharmaceuticals (IRWD), Pacira Pharmaceuticals (PCRX), Supernus Pharmaceuticals (SUPN), Horizon Pharma PLC (HZNP), Diplomat Pharmacy (DPLO), Eagle Pharmaceuticals (EGRX), Momenta Pharmaceuticals (MNTA), Lannett Company (LCI), Flexion Therapeutics (FLXN), Versartis (VSAR) and Karyopharm Therapeutics (KPTI).
How do I buy Hospira stock?
Shares of Hospira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Hospira stock cost?
One share of Hospira stock can currently be purchased for approximately $89.95.
Consensus Ratings for Hospira (NYSE:HSP) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Hospira (NYSE:HSP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Hospira (NYSE:HSP)Earnings History by Quarter for Hospira (NYSE:HSP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/29/2015||Q215||$0.78||$0.85||$1.18 billion||$1.20 billion||View||N/A|
|4/28/2015||Q115||$0.51||$0.97||$1.08 billion||$1.18 billion||View||N/A|
|2/12/2015||Q414||$0.41||$0.53||$1.12 billion||$1.13 billion||View||Listen|
|11/6/2014||Q314||$0.53||$0.74||$1.08 million||$1.15 billion||View||Listen|
|7/30/2014||Q214||$0.56||$0.72||$1.05 billion||$1.14 billion||View||Listen|
|4/30/2014||Q114||$0.49||$0.60||$1.02 billion||$1.10 billion||View||Listen|
|2/12/2014||Q413||$0.50||$0.51||$1.06 billion||$1.10 billion||View||Listen|
|7/31/2013||Q2 2013||$0.51||$0.55||$1.03 billion||$1.03 billion||View||Listen|
|5/1/2013||Q1 2013||$0.44||$0.52||$979.33 million||$884.00 million||View||Listen|
|2/13/2013||Q4 2012||$0.54||$0.55||$1.04 billion||$1.10 billion||View||Listen|
|11/7/2012||Q312||$0.45||$0.47||$987.67 million||$994.00 million||View||N/A|
Earnings Estimates for Hospira (NYSE:HSP)
Current Year EPS Consensus Estimate: $3.16 EPS
Next Year EPS Consensus Estimate: $3.66 EPS
Dividend History for Hospira (NYSE:HSP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Hospira (NYSE:HSP)Insider Trades by Quarter for Hospira (NYSE:HSP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/2/2015||Matthew R Stober||SVP||Sell||21,833||$87.49||$1,910,169.17|| |
|2/27/2015||Matthew R Stober||SVP||Sell||25,338||$87.47||$2,216,314.86|| |
|2/17/2015||Thomas E Werner||CFO||Sell||1,566||$87.35||$136,790.10|| |
|1/15/2015||Thomas E Werner||CFO||Sell||10,000||$61.56||$615,600.00|| |
|1/12/2015||Matthew R Stober||SVP||Sell||2,000||$61.80||$123,600.00|| |
|12/15/2014||Thomas E Werner||CFO||Sell||10,000||$60.86||$608,600.00|| |
|12/2/2014||Richard J Hoffman||CAO||Sell||21,850||$60.32||$1,317,992.00|| |
|11/25/2014||Marc J Yoskowitz||SVP||Sell||11,523||$59.93||$690,573.39|| |
|11/24/2014||Kenneth F Meyers||SVP||Sell||46,250||$59.66||$2,759,275.00|| |
|11/17/2014||Thomas E Werner||CFO||Sell||10,000||$57.73||$577,300.00|| |
|9/15/2014||Thomas E Werner||CFO||Sell||10,000||$52.74||$527,400.00|| |
|8/15/2014||Thomas E Werner||CFO||Sell||10,000||$55.13||$551,300.00|| |
|7/15/2014||Thomas E Werner||CFO||Sell||10,000||$51.50||$515,000.00|| |
|6/16/2014||Thomas E Werner||CFO||Sell||10,000||$50.82||$508,200.00|| |
|5/21/2014||Thomas Werner||CFO||Sell||30,000||$47.98||$1,439,400.00|| |
|5/16/2014||Connie Curran||Director||Sell||2,000||$47.44||$94,880.00|| |
|5/14/2014||Barbara Bowles||Director||Sell||2,000||$47.77||$95,540.00|| |
|5/13/2014||Richard Hoffman||CAO||Sell||15,000||$48.07||$721,050.00|| |
|5/12/2014||Brian Smith||SVP||Sell||40,000||$48.00||$1,920,000.00|| |
|3/14/2014||Matthew Stober||SVP||Sell||19,217||$42.28||$812,494.76|| |
|2/26/2014||Thomas Werner||CFO||Sell||20,000||$42.53||$850,600.00|| |
|9/11/2013||Richard J Hoffman||CAO||Sell||9,850||$39.38||$387,893.00|| |
|8/16/2013||Matthew Stober||SVP||Sell||4,990||$40.12||$200,198.80|| |
|6/7/2013||Sumant Ramachandra||SVP||Sell||23,702||$35.69||$845,924.38|| |
Headline Trends for Hospira (NYSE:HSP)
Latest Headlines for Hospira (NYSE:HSP)
Hospira (HSP) Chart for Thursday, May, 25, 2017